International Multi-site Implementation of Local Cell-Free Protein Biomanufacturing to Advance Health and Research Equity
Bibliographic record
Abstract
Limitations in global access to research and healthcare capacity undermine equity, sustainability, and resilience, particularly in resource-limited settings. Molecular diagnostics and biologic therapeutics are set to revolutionize medicine; however, our dependence on centralized biomanufacturing, and the concomitant cold chain logistics, restrict access to these benefits. While these constraints become particularly evident during global health crises, they reflect a chronic and unmet global challenge. Here, with research teams in North and South America and Asia, we challenge the conventional top-down paradigm by innovating community-driven solutions that empower underserved populations to actively participate in the bioeconomy, producing what they need, when, and where they need it. Our approach leverages decentralized, low-burden biomanufacturing technologies-built on cell-free protein synthesis and open-source hardware-to enable local, on-demand production of critical biologics, including high-value growth factors, vaccines, and diagnostic enzymes, demonstrating performance comparable to commercial gold standards. This platform, implemented at ten sites worldwide, supported patient trials targeting globally relevant pathogens, including SARS-CoV-2, chikungunya, and Oropouche viruses. Together, these initiatives lay the foundation for a new era of globally inclusive biomanufacturing, where innovation goes beyond geographic boundaries, and communities everywhere are empowered to respond to global challenges with enhanced speed, autonomy, and equity.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.014 | 0.004 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.001 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.001 | 0.002 |
| Scholarly communication | 0.003 | 0.002 |
| Open science | 0.002 | 0.008 |
| Research integrity | 0.002 | 0.003 |
| Insufficient payload (model declined to judge) | 0.011 | 0.002 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".